RESUMEN
BACKGROUND: Current clinical care for common bacterial STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Mycoplasma genitalium (MG)) involves empiric antimicrobial therapy when clients are symptomatic, or if asymptomatic, waiting for laboratory testing and recall if indicated. Near-to-patient testing (NPT) can improve pathogen-specific prescribing and reduce unnecessary or inappropriate antibiotic use in treating sexually transmitted infections (STI) by providing same-day delivery of results and treatment. METHODS: We compared the economic cost of NPT to current clinic practice for managing clients with suspected proctitis, non-gonococcal urethritis (NGU), or as an STI contact, from a health provider's perspective. With a microsimulation of 1000 clients, we calculated the cost per client tested and per STI- and pathogen- detected for each testing strategy. Sensitivity analyses were conducted to assess the robustness of the main outcomes. Costs are reported as Australian dollars (2023). RESULTS: In the standard care arm, cost per client tested for proctitis, NGU in men who have sex with men (MSM) and heterosexual men were the highest at $247.96 (95% Prediction Interval (PI): 246.77-249.15), $204.23 (95% PI: 202.70-205.75) and $195.01 (95% PI: 193.81-196.21) respectively. Comparatively, in the NPT arm, it costs $162.36 (95% PI: 161.43-163.28), $158.39 (95% PI: 157.62-159.15) and $149.17 (95% PI: 148.62-149.73), respectively. Using NPT resulted in cost savings of 34.52%, 22.45% and 23.51%, respectively. Among all the testing strategies, substantial difference in cost per client tested between the standard care arm and the NPT arm was observed for contacts of CT or NG, varying from 27.37% to 35.28%. CONCLUSION: We found that NPT is cost-saving compared with standard clinical care for individuals with STI symptoms and sexual contacts of CT, NG, and MG.
Asunto(s)
Enfermedades de Transmisión Sexual , Humanos , Masculino , Femenino , Enfermedades de Transmisión Sexual/diagnóstico , Enfermedades de Transmisión Sexual/economía , Enfermedades de Transmisión Sexual/tratamiento farmacológico , Gonorrea/diagnóstico , Gonorrea/economía , Gonorrea/tratamiento farmacológico , Australia , Adulto , Análisis Costo-Beneficio , Infecciones por Chlamydia/diagnóstico , Infecciones por Chlamydia/economía , Infecciones por Chlamydia/tratamiento farmacológico , Chlamydia trachomatis , Neisseria gonorrhoeae/aislamiento & purificación , Mycoplasma genitalium , Tamizaje Masivo/economía , Tamizaje Masivo/métodos , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/economía , Uretritis/diagnóstico , Uretritis/economía , Uretritis/tratamiento farmacológico , Uretritis/microbiologíaRESUMEN
Schaalia turicensis is facultative anaerobic Gram-positive bacillus that commonly inhabits the oropharynx, gastrointestinal, and genitourinary tract of healthy individuals. This organism has been co-isolated with Neisseria gonorrhoeae from 15-year-old Thai male patient with gonococcal urethritis in Bangkok, Thailand. In this study, we characterized the class 1 integron in S. turicensis isolate using whole-genome sequencing and bioinformatics analysis. Sequencing analysis confirmed the presence of an imperfect class 1 integron located on chromosome and a novel 24.5-kb-long composite transposon, named Tn7083. The transposon Tn7083 carried genes encoding chloramphenicol resistance (cmx), sulfonamide resistance (sul1), and aminoglycoside resistance [aph(6)-Id (strB), aph(3'')-Ib (strA), aph(3')-Ia].
Asunto(s)
Antibacterianos , Genoma Bacteriano , Gonorrea , Uretritis , Humanos , Masculino , Tailandia , Uretritis/microbiología , Gonorrea/microbiología , Antibacterianos/farmacología , Adolescente , Secuenciación Completa del Genoma , Pruebas de Sensibilidad Microbiana , Neisseria gonorrhoeae/genética , Neisseria gonorrhoeae/aislamiento & purificación , Neisseria gonorrhoeae/clasificación , Neisseria gonorrhoeae/efectos de los fármacos , Elementos Transponibles de ADN/genética , Farmacorresistencia Bacteriana/genéticaRESUMEN
BACKGROUND Urogenital bacterial infections have a high incidence in humans. The most frequent cause of infections of the urogenital tract is gram-negative bacteria. Antibiotics are very effective in curing infectious diseases but they are accompanied by health complications. Probiotics are live microorganisms that are believed to confer a beneficial effect on human health when consumed in adequate amounts. This study aimed to compare outcomes from antibiotic treatment with and without the use of probiotics in 897 patients with lower urogenital tract infections, including cystitis, urethritis, prostatitis, and vulvovaginitis. MATERIAL AND METHODS A total of 897 patients aged 18 to 55 years were included in this research. Patients were divided into an intervention group including 460 patients (254 women, 206 men) and a comparison group including 437 patients (240 women, 197 men). The probiotics received by patients were capsules of ProBalans®. The diagnosis of cystitis, urethritis, prostatitis, vulvovaginitis, and sexually transmitted infection was done using several tests, and antibiotics were used for treatment. Qualitative data were analyzed using the chi-square or Fisher exact test. RESULTS We found a significant difference regarding patients' impressions of improvement after therapy between patients in the intervention group and the comparison group. CONCLUSIONS Use of probiotics together with antibiotics in the treatment of urogenital tract infection can help to reduce the adverse effects of antibiotics, increase the efficiency of antibiotic therapy, and reduce bacterial resistance to antibiotics. However, further research is needed to confirm these potential health benefits.
Asunto(s)
Antibacterianos , Cistitis , Probióticos , Prostatitis , Uretritis , Vulvovaginitis , Humanos , Adulto , Probióticos/uso terapéutico , Masculino , Femenino , Persona de Mediana Edad , Antibacterianos/uso terapéutico , Cistitis/tratamiento farmacológico , Adolescente , Adulto Joven , Prostatitis/tratamiento farmacológico , Prostatitis/microbiología , Uretritis/tratamiento farmacológico , Uretritis/microbiología , Vulvovaginitis/tratamiento farmacológico , Vulvovaginitis/microbiología , Resultado del Tratamiento , Infecciones Urinarias/tratamiento farmacológicoAsunto(s)
Reacción en Cadena de la Polimerasa Multiplex , Infecciones por Ureaplasma , Ureaplasma urealyticum , Uretritis , Humanos , Uretritis/microbiología , Uretritis/diagnóstico , Masculino , Ureaplasma urealyticum/genética , Ureaplasma urealyticum/aislamiento & purificación , Infecciones por Ureaplasma/diagnóstico , Infecciones por Ureaplasma/microbiología , Adulto , Reacción en Cadena en Tiempo Real de la PolimerasaRESUMEN
BACKGROUND: Mycoplasma genitalium is a major contributor to persistent/recurrent urethritis cases. However, there are limited published studies on recent trends of persistent/recurrent urethritis. METHODS: A retrospective analysis was conducted of men presenting with symptomatic urethritis in 16 sexually transmitted disease (STD) clinics from 2015 to 2019. Poisson regression was used to assess trends in the annual proportions of urethritis episodes with follow-up (FU) characterized with persistent/recurrent urethritis symptoms. Results were also stratified by results of chlamydia (CT) and gonorrhea (NG) testing and treatment prescribed. RESULTS: There were 99,897 urethritis episodes, from 67,546 unique men. The proportion of episodes with persistent/recurrent symptomatic FU visits increased 50.8% over a 4-year period (annual percentage change [APC], 11.3%; 95% confidence interval [CI], 6.5-16.3). Similar trends were observed in nonchlamydial nongonococcal urethritis episodes (APC, 12.7%; 95% CI, 6.8-18.9) but increases among those positive for NG (APC, 12.1%; 95% CI, -2.3 to -28.5) or for CT (APC, 7.3%; 95% CI, -6.7 to 23.5) were not statistically significant. Among episodes who received azithromycin as first-line treatment, increases in the proportion of persistent/recurrent FU visits were observed (APC, 12.6%; 95% CI, 8.6-16.7). For episodes where first-line treatment was doxycycline, no significant increases were detected (APC, 4.3%; 95% CI, -0.3 to 9.2). CONCLUSIONS: We found an increase in the proportion of urethritis episodes with persistent or recurrent symptoms over time. Given these observed trends in episodes negative for NG or CT, an etiology not detectable by routine diagnostics was a likely factor in increased persistence, suggesting patients with urethritis may benefit from diagnostic testing for M. genitalium during an initial symptomatic presentation.
Asunto(s)
Infecciones por Mycoplasma , Mycoplasma genitalium , Recurrencia , Uretritis , Humanos , Uretritis/tratamiento farmacológico , Uretritis/diagnóstico , Uretritis/microbiología , Uretritis/epidemiología , Masculino , Mycoplasma genitalium/aislamiento & purificación , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/epidemiología , Estudios Retrospectivos , Adulto , Gonorrea/tratamiento farmacológico , Gonorrea/diagnóstico , Gonorrea/epidemiología , Adulto Joven , Infecciones por Chlamydia/tratamiento farmacológico , Infecciones por Chlamydia/diagnóstico , Infecciones por Chlamydia/epidemiología , Antibacterianos/uso terapéutico , Persona de Mediana Edad , Enfermedades de Transmisión Sexual/tratamiento farmacológico , Enfermedades de Transmisión Sexual/diagnóstico , Enfermedades de Transmisión Sexual/epidemiología , Azitromicina/uso terapéutico , Azitromicina/administración & dosificación , Adolescente , Doxiciclina/uso terapéuticoAsunto(s)
Uretritis , Humanos , Uretritis/diagnóstico , Uretritis/microbiología , Enfermedad Aguda , Violeta de Genciana , Fenazinas , MasculinoRESUMEN
Mycoplasma genitalium (M. genitalium) poses a significant public health challenge due to its association with non-gonococcal urethritis (particularly in men) and antimicrobial resistance. However, despite the prevalence of M. genitalium infections and the rise in resistance rates, routine testing and surveillance remain limited. This is the first study from Croatia that aimed to assess the prevalence and trends of resistance in M. genitalium strains isolated from male individuals by detecting macrolide and fluoroquinolone resistance genes. The study also aimed to explore the factors associated with resistance and changes in resistance patterns over time. Urine samples collected from male individuals in the Zagreb County and northwest region of Croatia between 2018 and 2023 were tested for M. genitalium with the use of molecular methods. Positive samples were subjected to DNA extraction and multiplex tandem polymerase chain reaction (MT-PCR) targeting genetic mutations associated with macrolide (23S rRNA gene) and fluoroquinolone (parC gene) resistance. Of the 8073 urine samples tested from 6480 male individuals (and following the exclusion of repeated specimens), we found that the prevalence of M. genitalium infection was 2.2%. Macrolide resistance was observed in 60.4% of strains, while fluoroquinolone resistance was found in 19.2%. Co-resistance to both antibiotics was present in 18.2% of cases. A statistically significant increase in fluoroquinolone resistance was noted over the study period (p = 0.010), but this was not evident for azithromycin resistance (p = 0.165). There were no statistically significant differences in resistance patterns between age groups, whereas re-testing of patients revealed dynamic changes in resistance profiles over time. The high burden of macrolide resistance and increasing fluoroquinolone resistance underscore the urgent need for comprehensive resistance testing and surveillance programs. The implementation of resistance-guided treatment strategies, along with enhanced access to molecular diagnostics, is pivotal for effectively managing M. genitalium infections.
Asunto(s)
Antibacterianos , Farmacorresistencia Bacteriana , Fluoroquinolonas , Macrólidos , Infecciones por Mycoplasma , Mycoplasma genitalium , Mycoplasma genitalium/genética , Mycoplasma genitalium/efectos de los fármacos , Mycoplasma genitalium/aislamiento & purificación , Humanos , Masculino , Fluoroquinolonas/farmacología , Fluoroquinolonas/uso terapéutico , Croacia/epidemiología , Macrólidos/farmacología , Macrólidos/uso terapéutico , Adulto , Infecciones por Mycoplasma/microbiología , Infecciones por Mycoplasma/epidemiología , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/orina , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana/genética , Persona de Mediana Edad , Adulto Joven , ARN Ribosómico 23S/genética , Adolescente , Uretritis/microbiología , Uretritis/epidemiología , Uretritis/tratamiento farmacológico , Pruebas de Sensibilidad MicrobianaRESUMEN
The occurrence of cysts and papulopustules along the midline penile raphe, as a complication of gonococcal urethritis, is considered an exceptional presentation. These lesions are related to developmental abnormalities in the fusion of the lower portion of the ventral abdominal wall during embryogenesis, which create small pathways along the raphe of the penis, prone to secondary infection in the presence of gonococcal urethritis. We present the case of a 25-year-old male who experienced these lesions twice, coinciding with two separate episodes of gonococcal urethritis following unprotected sex. Treatment with intramuscular ceftriaxone resolved both the urethritis and cystic lesions.
Asunto(s)
Antibacterianos , Ceftriaxona , Gonorrea , Neisseria gonorrhoeae , Pene , Uretritis , Humanos , Masculino , Gonorrea/diagnóstico , Gonorrea/tratamiento farmacológico , Adulto , Ceftriaxona/uso terapéutico , Ceftriaxona/administración & dosificación , Antibacterianos/uso terapéutico , Antibacterianos/administración & dosificación , Uretritis/microbiología , Uretritis/tratamiento farmacológico , Uretritis/diagnóstico , Neisseria gonorrhoeae/aislamiento & purificación , Pene/microbiología , Resultado del TratamientoRESUMEN
INTRODUCTION: For the first time, the accuracy and proficiency of ChatGPT answers on urogenital tract infection (UTIs) were evaluated. METHODS: The study aimed to create two lists of questions: frequently asked questions (FAQs, public-based inquiries) on relevant topics, and questions based on guideline information (guideline-based inquiries). ChatGPT responses to FAQs and scientific questions were scored by two urologists and an infectious disease specialist. Quality and reliability of all ChatGPT answers were checked using the Global Quality Score (GQS). The reproducibility of ChatGPT answers was analyzed by asking each question twice. RESULTS: All in all, 96.2 % of FAQs (75/78 inquiries) related to UTIs were correctly and adequately answered by ChatGPT, and scored GQS 5. None of the ChatGPT answers were classified as GQS 2 and GQS 1. Moreover, FAQs about cystitis, urethritis, and epididymo-orchitis were answered by ChatGPT with 100 % accuracy (GQS 5). ChatGPT answers for EAU urological infections guidelines showed that 61 (89.7 %), 5 (7.4 %), and 2 (2.9 %) ChatGPT responses were scored GQS 5, GQS 4, and GQS 3, respectively. None of the ChatGPT responses for EAU urological infections guidelines were categorized as GQS 2 and GQS 1. Comparison of mean GQS values of ChatGPT answers for FAQs and EAU urological guideline questions showed that ChatGPT was similarly able to respond to both question groups (p = 0.168). The ChatGPT response reproducibility rate was highest for the FAQ subgroups of cystitis, urethritis, and epididymo-orchitis (100 % for each subgroup). CONCLUSION: The present study showed that ChatGPT gave accurate and satisfactory answers for both public-based inquiries, and EAU urological infection guideline-based questions. Reproducibility of ChatGPT answers exceeded 90% for both FAQs and scientific questions.
Asunto(s)
Infecciones Urinarias , Humanos , Infecciones Urinarias/tratamiento farmacológico , Infecciones Urinarias/diagnóstico , Reproducibilidad de los Resultados , Encuestas y Cuestionarios , Cistitis/tratamiento farmacológico , Cistitis/diagnóstico , Masculino , Guías de Práctica Clínica como Asunto , Uretritis/diagnóstico , Epididimitis/diagnóstico , Epididimitis/tratamiento farmacológico , Orquitis/tratamiento farmacológico , Orquitis/diagnóstico , FemeninoRESUMEN
BACKGROUND: Sexual behavior may influence the composition of the male urethral microbiota, but this hypothesis has not been tested in longitudinal studies of men who have sex with men (MSM). METHODS: From December 2014 to July 2018, we enrolled MSM with nongonococcal urethritis (NGU) attending a sexual health clinic. Men attended 5 in-clinic visits at 3-week intervals, collected weekly urine specimens at home, and reported daily antibiotics and sexual activity on weekly diaries. We applied broad-range 16S rRNA gene sequencing to urine. We used generalized estimating equations to estimate the association between urethral sexual exposures in the prior 7 days (insertive oral sex [IOS] only, condomless insertive anal intercourse [CIAI] only, IOS with CIAI [IOS + CIAI], or none) and Shannon index, number of species (observed, oral indicator, and rectal indicator), and specific taxa, adjusting for recent antibiotics, age, race/ethnicity, HIV, and preexposure prophylaxis. RESULTS: Ninety-six of 108 MSM with NGU attended ≥1 follow-up visit. They contributed 1140 person-weeks of behavioral data and 1006 urine specimens. Compared with those with no urethral sexual exposures, those with IOS only had higher Shannon index ( P = 0.03 ) but similar number of species and presence of specific taxa considered, adjusting for confounders; the exception was an association with Haemophilus parainfluenzae . CIAI only was not associated with measured aspects of the urethral microbiota. IOS + CIAI was only associated with presence of H. parainfluenzae and Haemophilus . CONCLUSIONS: Among MSM after NGU, IOS and CIAI did not seem to have a substantial influence on measured aspects of the composition of the urethral microbiota.
Asunto(s)
Homosexualidad Masculina , Microbiota , Conducta Sexual , Uretra , Uretritis , Humanos , Masculino , Adulto , Uretra/microbiología , Uretritis/microbiología , ARN Ribosómico 16S/genética , Adulto Joven , Estudios Longitudinales , Persona de Mediana Edad , Minorías Sexuales y de GéneroRESUMEN
Mycoplasma genitalium (MG) is an emerging sexually transmitted infection, which appears to be a cause of urethritis and cervicitis and has been associated with pelvic inflammatory disease (PID), epididymitis, proctitis, infertility, complications during pregnancy, and human immunodeficiency virus (HIV) transmission. Three Food and Drug Administration (FDA) approved tests are available. Testing should be focused to avoid inappropriate antibiotic use. The Center of Disease Control and Prevention (CDC) guidelines recommend testing for persistent male urethritis, cervicitis, and proctitis and state that testing should be considered in cases of PID. Testing is also recommended for sexual contacts of patients with MG. Testing is not recommended in asymptomatic patients, including pregnant patients, who do not have a history of MG exposure. Although resistance-guided therapy is recommended, there are currently no FDA approved tests for MG macrolide resistance, and tests are not widely available in the United States. The CDC recommends 2-step treatment with doxycycline followed by azithromycin or moxifloxacin. Moxifloxacin is recommended if resistance testing is unavailable or testing demonstrates macrolide resistance..
Asunto(s)
Infecciones por Mycoplasma , Mycoplasma genitalium , Enfermedad Inflamatoria Pélvica , Proctitis , Uretritis , Cervicitis Uterina , Embarazo , Femenino , Humanos , Masculino , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Uretritis/diagnóstico , Uretritis/tratamiento farmacológico , Uretritis/complicaciones , Moxifloxacino/uso terapéutico , Cervicitis Uterina/complicaciones , Cervicitis Uterina/tratamiento farmacológico , Macrólidos/uso terapéutico , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/complicaciones , Farmacorresistencia Bacteriana , Enfermedad Inflamatoria Pélvica/diagnóstico , Enfermedad Inflamatoria Pélvica/tratamiento farmacológico , Enfermedad Inflamatoria Pélvica/complicaciones , Proctitis/complicaciones , Proctitis/tratamiento farmacológico , Atención Primaria de SaludRESUMEN
Tyson's glands are sebaceous glands located on each side of the frenulum that communicate with the preputial sac, and their inflammation can be an infrequent complication of urethritis. We describe a rare case that presented with urethral discharge and parafrenular swelling with mucopurulent discharge a week after an unprotected sexual encounter. The patient was empirically treated with 500 mg of ceftriaxone intramuscularly and 100 mg of doxycycline every 12 h for 14 days with symptomatic resolution. The urethral swab culture and the urine polymerase chain reaction (PCR) were negative for Neisseria gonorrhoeae and Chlamydia trachomatis, therefore, and given the response to treatment, nongonococcal tysonitis was diagnosed.
Asunto(s)
Infecciones por Chlamydia , Gonorrea , Uretritis , Humanos , Infecciones por Chlamydia/diagnóstico , Uretritis/diagnóstico , Uretritis/tratamiento farmacológico , Uretritis/etiología , Chlamydia trachomatis , Neisseria gonorrhoeae/genética , Doxiciclina/uso terapéutico , Gonorrea/complicaciones , Gonorrea/diagnóstico , Gonorrea/tratamiento farmacológicoRESUMEN
Idiopathic urethritis (IU) is difficult to manage and there is no standarized therapy. The technique of local steroid injection (LSI) for the treatment of IU in children and the results of the patients undergoing LSI from 2020 to 2021 in a single center are presented. Seven patients with IU underwent LSI. An internal urethrotomy was also performed in two patients with stricture. Complete resolution of symptoms and signs occurred in six patients. The remaining patient did not achieve total remission but did substantially improve symptoms. LSI seems to be an effective alternative for treatment of IU in children.
Asunto(s)
Uretritis , Niño , Humanos , Uretritis/tratamiento farmacológico , Uretritis/diagnóstico , Uretra , Terapia Conductista , Recurrencia , EsteroidesRESUMEN
Posterior urethritis is diagnosed in prepubertal or pubertal boys mainly with terminal asymptomatic haematuria or postmicturition blood spotting on the meatus or in the underwear. It presents with typical changes in the bulbar urethra (hyperaemia, oedema and denuded mucosa) without laboratory or radiological findings. The pathology is self-limiting with a very good prognosis. This condition is most likely caused by dysfunctional voiding and urotherapy with biofeedback therapy offers good treatment results. Although urethrocystoscopy is the only way to confirm the diagnosis, the patient should be prevented from having a (usually unnecessary) urethrocystoscopy and the relatives should be reassured.
Asunto(s)
Uretritis , Masculino , Femenino , Humanos , Uretritis/diagnóstico , Hematuria/etiología , Uretra/diagnóstico por imagen , Resultado del Tratamiento , PronósticoRESUMEN
BACKGROUND: In South Africa, Neisseria gonorrhoeae , which is the predominant cause of male urethritis, is treated syndromically using dual ceftriaxone and azithromycin therapy. We determined antimicrobial susceptibilities of N. gonorrhoeae isolates from urethral discharge specimens, and genetically characterised those with elevated minimum inhibitory concentrations (MICs) for first-line antimicrobials. METHODS: Routine antimicrobial susceptibility testing (AST) of N. gonorrhoeae isolates included E-test for ceftriaxone, cefixime and gentamicin and agar dilution for azithromycin and spectinomycin. Neisseria gonorrhoeae Sequence Typing for Antimicrobial Resistance (NG-STAR) was performed for isolates with elevated MICs to identify antimicrobial resistance (AMR) determinants, and Neisseria gonorrhoeae Multi-Antigen Sequence Typing (NG-MAST) was used to determine strain relatedness. RESULTS: N. gonorrhoeae was cultured from urethral discharge swab specimens obtained from 196 of 238 (82.4%) men presenting to a primary healthcare facility in Johannesburg in 2021. All viable isolates were susceptible to extended-spectrum cephalosporins. Four isolates had high azithromycin MICs ranging from 32mg/L to >256mg/L and grouped into two novel NG-MAST and NG-STAR groups. Two isolates from Group 1 (NG-MAST ST20366, NG-STAR ST4322) contained mutated mtrR (G45D) and 23S rRNA (A2059G) alleles, while the two isolates from Group 2 (NG-MAST ST20367, NG-STAR ST4323) had different mutations in mtrR (A39T) and 23S rRNA (C2611T). CONCLUSIONS: We report the first cases of high-level azithromycin resistance in N. gonorrhoeae from South Africa. Continued AMR surveillance is critical to detect increasing azithromycin resistance prevalence in N. gonorrhoeae , which may justify future modifications to the STI syndromic management guidelines.
Asunto(s)
Gonorrea , Uretritis , Masculino , Humanos , Femenino , Azitromicina/farmacología , Azitromicina/uso terapéutico , Neisseria gonorrhoeae/genética , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Ceftriaxona/farmacología , Ceftriaxona/uso terapéutico , Gonorrea/tratamiento farmacológico , Gonorrea/epidemiología , Sudáfrica , ARN Ribosómico 23S/genética , Uretritis/tratamiento farmacológico , Farmacorresistencia Bacteriana/genéticaRESUMEN
BACKGROUND: Mycoplasma genitalium (MG) is an emerging sexually transmitted infection. Treatment of MG is complicated by increasing resistance to primary treatment regimens, including macrolides and fluoroquinolones. Understanding the various clinical presentations and relative effectiveness of treatments for MG is crucial to optimizing care. METHODS: Patients with a positive MG nucleic acid amplification test between July 1, 2019, and June 30, 2021, at a large health system in New York City were included in a retrospective cohort. Demographics, clinical presentations, coinfections, treatment, and follow-up microbiologic tests were obtained from the electronic medical record. Associations with microbiologic cure were evaluated in bivariate and multivariable logistic regression models. RESULTS: Five hundred two unique patients had a positive MG nucleic acid amplification test result during the study period. Male individuals presented predominantly with urethritis (117 of 187 [63%]) and female individuals with vaginal symptoms (142 of 315 [45%]). Among patients with follow-up testing who received a single antibiotic at the time of treatment, 43% (90 of 210) had persistent infection and 57% (120 of 210) had microbiologic cure. Eighty-two percent of patients treated with moxifloxacin had microbiologic cure compared with 41% of patients receiving azithromycin regimens ( P < 0.001). In multivariable analysis, treatment with moxifloxacin was associated with 4 times the odds of microbiologic cure relative to low-dose azithromycin (adjusted odds ratio [aOR], 4.18; 95% confidence interval, 1.73-10.13; P < 0.01). CONCLUSIONS: Clinical presentations of MG vary, with urethritis or vaginal symptoms in most cases. Among patients who received a single antibiotic, only treatment with moxifloxacin was significantly associated with microbiologic cure relative to low-dose azithromycin.
Asunto(s)
Infecciones por Mycoplasma , Mycoplasma genitalium , Uretritis , Humanos , Masculino , Femenino , Azitromicina/uso terapéutico , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/epidemiología , Moxifloxacino/uso terapéutico , Uretritis/diagnóstico , Uretritis/tratamiento farmacológico , Uretritis/epidemiología , Estudios Retrospectivos , Ciudad de Nueva York/epidemiología , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Resultado del Tratamiento , Macrólidos/uso terapéutico , Atención a la Salud , Farmacorresistencia BacterianaRESUMEN
We report the case of a 19-year-old Malian patient, who presented with urethritis and a vesicular rash during the summer of 2022, following a probable heterosexual intercourse. The epidemic context among the male homosexual population and the clinical picture without genital lesions or lymphadenopathy allowed us to discuss both chickenpox and mpox, the latter being finally confirmed by the detection of Monkeypox virus DNA from vesicular fluid.
Asunto(s)
Exantema , Mpox , Uretritis , Humanos , Masculino , Adulto Joven , Exantema/etiología , Homosexualidad Masculina , Migrantes , Uretritis/diagnóstico , Uretritis/etiología , Enfermedades Cutáneas Vesiculoampollosas/etiología , Mpox/complicaciones , Mpox/diagnóstico , Mpox/virología , Monkeypox virus/aislamiento & purificaciónRESUMEN
Mycoplasma genitalium (MG) is a common cause of non-gonococcal urethritis, but a role in acute or chronic prostatitis has not been described. We describe the case of a 42-year-old man with recurrent urinary tract infections since 2018 who developed chronic prostatitis despite several and prolonged antibiotic courses. Multiparametric prostatic magnetic resonance showed peripheral inflammatory alterations. A 4-glass Meares-Stamey test detected MG in the third voided bladder (VB3) sample. Moxifloxacin 400 mg daily for 28 days resulted in sustained clinical and microbiological cure.
Asunto(s)
Infecciones por Mycoplasma , Mycoplasma genitalium , Prostatitis , Uretritis , Masculino , Humanos , Adulto , Prostatitis/diagnóstico , Prostatitis/tratamiento farmacológico , Antibacterianos/uso terapéutico , Uretritis/diagnóstico , Uretritis/tratamiento farmacológico , Uretritis/microbiología , Enfermedad Crónica , Infecciones por Mycoplasma/complicaciones , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/tratamiento farmacológicoRESUMEN
Neisseria meningitidis (Nm) is a bacterial pathogen responsible for invasive meningococcal disease. Though typically colonizing the nasopharynx, multiple outbreaks of meningococcal urethritis were first reported in 2015-2016; outbreaks originally presumed to be caused by Neisseria gonorrhoeae (Ng). Genomic analysis revealed that the Nm isolates causing these outbreaks were a distinct clade, and had integrated gonococcal DNA at multiple genomic sites, including the gonococcal denitrification apparatus aniA-norB, a partial gonococcal operon of five genes containing ispD, and the acetylglutamate kinase gene argB with the adjacent gonococcal locus NGO0843. The urethritis isolates had also deleted the group C capsule biosynthesis genes cssA/B/C and csc, resulting in loss of capsule. Collectively, these isolates form the N. meningitidis urethritis clade (NmUC). Genomic analysis of recent (2016-2022) NmUC isolates revealed that the genomic features have been maintained in the clade, implying that they are important for NmUC's status as a urogenital pathogen. Furthermore, the analysis revealed the emergence of a sub-clade, designated NmUC-B, phylogenetically separated from the earlier NmUC-A. This sub-clade has integrated additional gonococcal alleles into the genome, including alleles associated with antimicrobial resistance. NmUC continues to adapt to a urethral niche and evolve as a urogenital pathogen.